The global APOL1-mediated kidney disease market is set to witness remarkable growth, projecting an escalation from USD 3779.9 million in 2023 to an impressive USD 5753.9 million by 2033, reflecting a robust Compound Annual Growth Rate (CAGR) of 4.3%. This growth highlights a pressing need for innovative therapies designed to tackle the root cause of this debilitating condition.
APOL1-mediated kidney disease poses a significant healthcare challenge, marked by limited treatment options that primarily manage symptoms such as swelling, fluid retention, and hypertension. Central to this condition is the overexpression of the APOL1 protein, which drives nephropathic symptoms and ultimately leads to kidney failure. Addressing this fundamental cause is crucial for revolutionizing patient outcomes.
Request A Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-12115
In response to this pressing need, pioneering efforts are underway to develop targeted therapies aimed at reducing APOL1 protein levels in affected individuals. By addressing the fundamental molecular mechanism driving the disease, these novel treatments hold the potential to revolutionize the landscape of APOL1-mediated kidney disease management.
The market trajectory for APOL1-mediated kidney illness has been steadily ascending, with a valuation of US$ 3.0 billion in 2020. According to Future Market Insights (FMI), this upward trend is expected to persist, with a stable CAGR exceeding 4% projected over the forecast period (2020-2030). This sustained growth underscores the growing recognition of APOL1-mediated kidney disease as a significant healthcare concern demanding innovative solutions.
As stakeholders across the healthcare continuum unite in their commitment to combat APOL1-mediated kidney disease, the stage is set for transformative advancements that promise to enhance patient well-being and reshape the treatment landscape.
Key Takeaways from APOL1 Mediated kidney Diseases Market Study
- Chronic kidney diseases account for more than 95% of all the APOL1 mediated diseases. Increasing prevalence of hypertension associated kidney diseases will increase treatment needs over the forecast period
- North America accounts for over 3/4th of the global market. High prevalence of the disease among people with African American ancestry makes North America the leader in this market
- Pipeline drugs under development are targeted to be launched in the U.S., catapulting it as a highly lucrative pocket
- Key players are focusing on extensive research and development for targeted therapy towards APOL1
- The COVID-19 outbreak did not have any impact on the APOl1 mediated treatment market. All patients with indications like end stage kidney disorders were attended amidst COVID-19 due to the severity of kidney disease
“Increasing research and development for discovery of underlying cause of APOL1 mediated kidney disease and its targeted therapy will propel the market growth in the future,” says FMI analyst
For More Report Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-12115
Market Competition:
The APOL1-mediated kidney disease market is highly competitive, characterized by several prominent industry players actively involved in its development. Leading companies such as Vertex Pharmaceuticals Incorporated, Ionis Pharmaceuticals, AstraZeneca, Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, and Roche Holding AG are investing significantly in advancing treatments for APOL1-mediated kidney disease (AMKD).
Recent market developments include:
Major industry players are employing organic growth strategies such as acquisitions, mergers, partnerships, and collaborations to broaden their product offerings, thereby driving growth in the global APOL1-mediated kidney disease market.
- On November 4, 2022, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) partnered with basketball Hall-of-Famer Alonzo Mourning to launch “Power Forward,” an educational initiative aimed at raising awareness about APOL1-mediated kidney disease (AMKD) and emphasizing the importance of early diagnosis and genetic testing.
- In July 2022, AstraZeneca collaborated with the Indian Society of Nephrology to establish the Chronic Kidney Disease Academy, focusing on enhancing knowledge and treatment practices related to chronic kidney diseases.
Key Segments Profiled In The Apol1 Mediated Kidney Disease Market:
By Indication:
- Chronic Kidney Disease
- Focal segmental glomerulosclerosis (FSGS)
- Human immunodeficiency virus (HIV)-associated Nephropathy
- Hypertension-associated Kidney Disease
- End-Stage Kidney Disease
Region
- North America (U.S.)
- Europe
- MEA
A Full Report Overview: https://www.futuremarketinsights.com/checkout/12115
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
